2022
Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis
Stone CA, Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, Mancini C, Wolfson AR, Saff RR, Samarakoon U, Hong DI, Koo G, Chow TG, Gruchalla R, Liao JX, Kuster JK, Price C, Ahola C, Khan DA, Phillips EJ, Banerji A, Blumenthal KG. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 458-465.e1. PMID: 36108922, PMCID: PMC9468049, DOI: 10.1016/j.jaip.2022.08.048.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 VaccinesHumansHypersensitivity, ImmediateLatent Class AnalysisPhenotypeRetrospective StudiesRNA, MessengerConceptsMRNA COVID-19 vaccineNovel clinical phenotypesCOVID-19 vaccineDose 1Second doseClinical phenotypeObjective signsLatent class analysisMRNA coronavirus disease 2019 (COVID-19) vaccinesDose toleranceAllergy/immunology specialistsMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesSelf-limiting symptomsFirst-dose reactionsU.S. academic medical centersLog-binomial regressionCOVID-19 vaccinationDistinct clinical phenotypesAcademic medical centerImmediate reactionsImmunology specialistsClass analysisAllergic symptomsRetrospective studyDefining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency
Shin JJ, Par-Young J, Unlu S, McNamara A, Park HJ, Shin MS, Gee RJ, Doyle H, Afinogenova Y, Zidan E, Kwah J, Russo A, Mamula M, Hsu FI, Catanzaro J, Racke M, Bucala R, Wilen C, Kang I. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. Journal Of Clinical Immunology 2022, 42: 1137-1150. PMID: 35713752, PMCID: PMC9203263, DOI: 10.1007/s10875-022-01296-4.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, ViralCD8-Positive T-LymphocytesCommon Variable ImmunodeficiencyCOVID-19COVID-19 VaccinesHumansImmunity, CellularImmunoglobulin AImmunoglobulin GMRNA VaccinesPrimary Immunodeficiency DiseasesRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationVaccinesVaccines, SyntheticConceptsCommon variable immune deficiencyT cellsImmune responseIgG responsesCVID patientsMRNA vaccinesB cellsCoronavirus disease 2019 (COVID-19) mRNA vaccinesCOVID-19 mRNA vaccinesBaseline immune profileHistory of autoimmunityPrimary antibody deficiencyT cell responsesCellular immune responsesPoor immune responseVariable immune deficiencyMemory B cellsSARS-CoV-2 spike proteinBaseline IgGCVID diagnosisEM CD8Immunological predictorsPAD cohortSpecific CD4Immune profile
2021
Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.Peer-Reviewed Original ResearchMeSH Keywords2019-nCoV Vaccine mRNA-1273AdultAgedBNT162 VaccineCOVID-19 VaccinesFemaleHumansMaleMiddle AgedRetrospective StudiesTime Factors